Cooperative Agreement 7200AA19FA00009

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,553,810 to the University of Maryland, Baltimore to conduct genomic surveillance for artemisinin resistance in Africa. The project aims to identify parasite genetic adaptations and functional pathways associated with resistance to artemisinin-based combination therapies, the first-line treatment for malaria in...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $702,204 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the London School of Hygiene and Tropical Medicine (LSHTM) to conduct research on complex malaria in India. The key products and services to be delivered through this 5-year project include: Monitoring the changing epidemiology of malaria in Odisha, India through a 4-year community-based cohort study to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $335,559 to the University of North Carolina at Chapel Hill to conduct a pilot randomized controlled trial on the feasibility, acceptability, and preliminary effectiveness of a Focal Mass Drug Administration (FMDA) program for household members of pregnant women to protect against malaria in pregnancy (MIP). The key...

This Project Grant award from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program, with the CFDA number 47.070, provides $174,544 to the University of North Carolina at Charlotte (UNC Charlotte) to develop an integrated geospatial framework using advanced machine learning techniques to map disease transmission risk for mosquito-borne illnesses in Southern Africa. The key products and services to be delivered under this 2-year award include:...

This Project Grant award of $743,488.00 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under CFDA Program 93.865 Child Health and Human Development Extramural Research, aims to examine the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa. The research objectives are to: 1) characterize the mechanisms mediating the effects of sulfadoxine-pyrimethamine (SP) and dihydroartemisinin-piperaquine...

This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...

This Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 - International Research and Research Training) will provide $108,916 to Kamuzu University of Health Sciences in Malawi to characterize the pharmacokinetic and safety profiles of the antimalarial drugs artemether-lumefantrine plus amodiaquine (ALAQ) in two key target populations: children with severe acute malnutrition and adults living with HIV on dolutegravir-based antiretroviral...

This $3,850,000 Project Grant awarded on September 18, 2023 by the U.S. Agency for International Development (USAID) under the Foreign Assistance for Programs Overseas (CFDA 98.001) program will support Maisha Healthcare, Inc., a for-profit, woman-owned small business, in scaling a digital approach to targeted malaria treatment in Uganda over a 3-year period. The funded activities are intended to promote long-term and equitable economic growth and advance U.S. foreign policy objectives globally,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $832,071 to Seattle Children's Hospital to develop a universal transmission-blocking vaccine against malaria. The key products and services to be delivered include: Developing potent transmission-reducing monoclonal antibodies that can block vector infection across Plasmodium falciparum and Plasmodium vivax species. This...

This Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to study molecular mechanisms of Plasmodium parasite invasion in Anopheles mosquito midguts to identify novel targets for transmission-blocking malaria vaccines. The key products and services to be delivered under this award include: Functional characterization of identified mosquito and parasite proteins that mediate...